鞘内化疗联合放疗治疗脑转移瘤40例疗效观察

Curative effect of intrathecal chemotherapy combined with radiotherapy on brain metastatic tumor in 40 cases

目的观察鞘内化疗联合放疗治疗脑转移瘤的疗效。方法经影像学及病理学诊断为脑转移瘤患者40例，随机分为治疗组15例，予恩度15mg＋甲氨蝶呤15mg＋地塞米松5mg鞘内化疗联合放疗治疗，对照组25例仅给予放疗，比较两组1年复发率、无复发生存时间、治疗前后患者生活质量变化及药物不良反应。结果治疗组与对照组患者1年复发率、无复发生存时间、治疗前后患者生活质量变化等方面比较差异有统计学意义（P〈0．05）。主要不良反应有头昏、骨髓抑制，腹痛、腹胀，腰痛，脱发等。结论对脑转移瘤采用鞘内化疗联合放疗能有效提高生存质量、延长寿命，其不良反应小。

Objective To observe the effect of intrathecal chemotherapy combined with radiotherapy on brain metastases tumor. Methods Forty patients were diagnosed with brain metastatic tumor by imaging and pathology, and were randomly divided into treatment group（ 15 cases） and control group （25 cases）, and received Endostar 15 mg ＋ methotrexate 15 mg ＋ dexamethasone 5 mg intrathecal chemotherapy combined with radiation therapy in treatment group. Control group only had radiation therapy. The one year recurrence rate, relapse-free survival time and quality of life changes of the patients be- fore and after treatment and drug adverse reaction were compared between the two groups. Results The one year recurrence rate, relapse-free survival time and quality of life changes of the patients before and after treatment had statistically significant differences between the two groups （ P 〈 0. 05 ）. Main side re- actions were dizziness, bone marrow suppression, abdominal pain, abdominal distension, lumbago, hair loss, etc. Conclusions Intrathecal chemotherapy combined with radiotherapy for cerebral metastases is effective to improve the quality of survival, prolong life, its side reaction is small.